Mizuho Medy Co Ltd operates within the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Mizuho Medy Co Ltd with three other
pharmaceutical manufacturers in Asia:
BioSino Bio-technology and Science Inc
sales of 295.13 million Chinese Renmimbi [US$43.04 million]
Kainos Laboratories, Inc.
(4.70 billion Japanese Yen [US$41.53 million]
of which 52%
was immunological business), and
based in China
(302.89 million Chinese Renmimbi [US$44.17 million]
of which 94%
was Reagent Income).